EPS for Johnson & Johnson (JNJ) Expected At $2.03

September 15, 2018 - By Richard Slagle

Johnson & Johnson (NYSE:JNJ) LogoInvestors sentiment increased to 0.97 in 2018 Q2. Its up 0.04, from 0.93 in 2018Q1. It is positive, as 36 investors sold Johnson & Johnson shares while 806 reduced holdings. 114 funds opened positions while 704 raised stakes. 1.84 billion shares or 8.07% more from 1.71 billion shares in 2018Q1 were reported.
Clinton Group holds 0% or 3,939 shares in its portfolio. Kdi Prns Ltd Limited Liability Company accumulated 3.29% or 84,939 shares. Outfitter Advisors Ltd owns 11,962 shares or 0.66% of their US portfolio. Vident Advisory Ltd Limited Liability Company owns 8,325 shares. Diversified Trust invested 0.33% of its portfolio in Johnson & Johnson (NYSE:JNJ). Spears Abacus Advsrs Ltd Liability Corp owns 58,139 shares or 0.92% of their US portfolio. Evergreen Capital Mngmt Limited Liability Com invested 0.64% in Johnson & Johnson (NYSE:JNJ). Randolph holds 3.45% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 153,851 shares. Boston Research & Inc reported 9,355 shares stake. Moreover, Albion Fincl Gp Ut has 0.48% invested in Johnson & Johnson (NYSE:JNJ). Moreover, Efg Asset Mgmt (Americas) has 0.17% invested in Johnson & Johnson (NYSE:JNJ). Shikiar Asset stated it has 3,976 shares or 0.2% of all its holdings. Karpas Strategies Ltd Company holds 7.22% or 137,470 shares in its portfolio. First Long Island Invsts reported 102,122 shares stake. Armstrong Henry H Associate invested 10.42% of its portfolio in Johnson & Johnson (NYSE:JNJ).

Since August 27, 2018, it had 0 insider purchases, and 2 sales for $4.99 million activity. Kapusta Ronald A had sold 7,899 shares worth $1.08M.

Analysts expect Johnson & Johnson (NYSE:JNJ) to report $2.03 EPS on October, 16.They anticipate $0.13 EPS change or 6.84 % from last quarter’s $1.9 EPS. JNJ’s profit would be $5.45 billion giving it 17.18 P/E if the $2.03 EPS is correct. After having $2.10 EPS previously, Johnson & Johnson’s analysts see -3.33 % EPS growth. The stock decreased 0.29% or $0.4 during the last trading session, reaching $139.49. About 4.53 million shares traded. Johnson & Johnson (NYSE:JNJ) has risen 5.07% since September 15, 2017 and is uptrending. It has underperformed by 10.55% the S&P500.

Johnson & Johnson (NYSE:JNJ) Ratings Coverage

Among 9 analysts covering Johnson & Johnson (NYSE:JNJ), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. Johnson & Johnson had 13 analyst reports since March 23, 2018 according to SRatingsIntel. Stifel Nicolaus maintained the stock with “Hold” rating in Wednesday, April 18 report. The firm earned “Neutral” rating on Thursday, July 12 by Goldman Sachs. The stock has “Outperform” rating by Credit Suisse on Friday, April 20. The stock has “Buy” rating by Leerink Swann on Wednesday, April 18. Credit Suisse maintained the stock with “Buy” rating in Tuesday, June 12 report. The stock of Johnson & Johnson (NYSE:JNJ) earned “Buy” rating by Leerink Swann on Thursday, May 17. The rating was maintained by Morgan Stanley on Tuesday, April 10 with “Equal-Weight”. The firm has “Buy” rating by Wells Fargo given on Wednesday, April 18. The firm has “Buy” rating by Jefferies given on Friday, March 23. The stock of Johnson & Johnson (NYSE:JNJ) earned “Buy” rating by Credit Suisse on Thursday, April 12.

Johnson & Johnson, together with its subsidiaries, researches and develops, makes, and sells various products in the health care field worldwide. The company has market cap of $374.22 billion. It operates through three divisions: Consumer, Pharmaceutical, and Medical Devices. It has a 277.32 P/E ratio. The Consumer segment offers baby care products under the JOHNSONÂ’S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSONÂ’S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Seekingalpha.com which released: “Johnson & Johnson (JNJ) CEO Alex Gorsky Presents at 2018 Wells Fargo 13th Annual Healthcare Conference …” on September 06, 2018, also Seekingalpha.com with their article: “Johnson & Johnson (JNJ) Pharmaceutical Business Review Conference (Transcript)” published on September 13, 2018, Seekingalpha.com published: “Johnson & Johnson (JNJ) Management Presents at Barclays Global Consumer Staples Conference Call (Transcript)” on September 06, 2018. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Seekingalpha.com and their article: “Dividend Champion Spotlight: Johnson & Johnson” published on September 02, 2018 as well as Seekingalpha.com‘s news article titled: “Breakout Alert: Buy Johnson & Johnson” with publication date: August 20, 2018.

Johnson & Johnson (NYSE:JNJ) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.